Impact of systemic immune-inflammation index and its evaluation of optimal threshold in patients with limited-stage small cell lung cancer: a retrospective study based on 572 cases
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The systemic immune-inflammation index (SII) is an independent adverse prognostic factor for limited-stage small cell lung cancer (LS-SCLC). Elevated SII indicates poorer survival outcomes in LS-SCLC patients.
Area Of Science
- Oncology
- Immunology
- Biostatistics
Background
- Inflammation plays a role in cancer progression.
- The systemic immune-inflammation index (SII) is an emerging prognostic marker in various cancers.
- Limited research exists on SII's prognostic value in limited-stage small cell lung cancer (LS-SCLC).
Purpose Of The Study
- To determine the optimal threshold for SII in LS-SCLC patients.
- To investigate the association between SII and survival outcomes in LS-SCLC.
- To establish SII as a prognostic marker for LS-SCLC.
Main Methods
- Retrospective study of 572 LS-SCLC patients.
- Outcome-based method to determine optimal SII thresholds.
- Time-dependent ROC curves to assess SII's predictive ability.
Main Results
- Optimal SII thresholds for OS and PFS were identified as 760.6.
- Patients with low SII exhibited significantly improved OS and PFS compared to high SII groups.
- Multivariable analysis confirmed SII as an independent prognostic factor for OS and PFS.
Conclusions
- Elevated SII is an independent adverse prognostic factor for LS-SCLC.
- SII can be utilized to predict survival outcomes in LS-SCLC patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.